Ovid Therapeutics
137 articles about Ovid Therapeutics
-
It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.
-
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
12/1/2020
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced topline results from the Company’s Phase 3 NEPTUNE clinical trial of OV101 (gaboxadol) for the treatment of Angelman syndrome.
-
Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress
11/23/2020
Abstracts will be presented from the TAK-935/OV935 (soticlestat) clinical development program in Dravet syndrome or Lennox-Gastaut syndrome (Phase 2 ELEKTRA study) and OV101 (gaboxadol) clinical development program in Angelman syndrome (Phase 2 STARS study)
-
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
11/12/2020
On track to report topline results from pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome in Q4 2020 Reported positive ELEKTRA results; Ovid and Takeda plan to initiate phase 3 registrational program of OV935/TAK935 (soticlestat) in Dravet Syndrome and Lennox-Gastaut syndrome
-
Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program
10/14/2020
Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, announced it will host an educational webinar on Thursday, October 22, at 1:00 p.m. ET to review multiple aspects of Angelman syndrome, including its biological mechanism, and the Company’s OV101 development program.
-
Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Congress
10/12/2020
Four abstracts from the OV101 (gaboxadol) clinical development program in Angelman Syndrome and Fragile X Syndrome to be presented
-
Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies
9/30/2020
Results from signal-finding, pilot Phase 2 open-label ARCADE study and ENDYMION long-term extension study in CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) show seizure frequency reduction over time In CDD patients, median motor seizure frequency reduction was 24% in the ARCADE study, increasing to a 50% reduction in ENDYMION long-term extension study Clinical Global Impression of Change (CGI-C) and Caregiver Global Impression of Change (Care GI-C) suggest improvements beyond
-
Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
9/11/2020
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020, at 2:00 p.m. ET. A live audio webcast of the discussion can be accessed through the Events & Presentations section of the Company's w
-
Clinical Catch-Up: August 24-28
8/31/2020
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look. -
Takeda Pharmaceutical and Ovid Therapeutics announced on Tuesday that they have gathered positive data from their Phase II ELEKTRA study of soticlestat in children with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS).
-
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
8/25/2020
Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, today announced the pricing of an underwritten offering (the “Offering”) of 6,250,000 shares of its common stock. The offering price of each share of common stock was $8.00. The Offering is expected to close on August 27, 2020, subject to customary closing conditions. Cowen and Wi
-
Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
8/10/2020
Announces completion of enrollment in the pivotal Phase 3 NEPTUNE trial with OV101 in Angelman syndrome; topline results expected in Q4 2020 Multiple data readouts for soticlestat expected in Q3 2020, including from the randomized Phase 2 ELEKTRA trial in Dravet syndrome and Lennox-Gastaut syndrome, the Phase 2 ARCADE trial in CDKL5 deficiency disorder and Dup15q syndrome and the ENDYMION open-label extension study Receipt of Rare Pediatric Disease Designation by the FDA for OV101 for the
-
Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020
8/5/2020
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., MBA, President and Chief Medical Officer, will participate in a panel discussion at the William Blair Biotech Focus Conference 2020. The panel is titled, “New Therapies Impacting the Epilepsy Treatment Landscape,” and will be held on Thursday, A
-
Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome
7/23/2020
Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing the underlying genetic cause of Angelman syndrome
-
Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe
7/13/2020
Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union and other countries in the European Economic Area (Switzerland, Turkey and the United Kingdom) and Russia
-
Angelman Syndrome is a genetic disorder that mostly affects the nervous system.
-
Ovid Therapeutics Added to Russell 2000® and Russell 3000® Indexes
6/29/2020
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Russell 2000 ® and the Russell 3000 ® indexes following the annual reconstitution, effective after the U.S. market opens today, June 29, 2020. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of May 8, r
-
Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome
6/19/2020
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to OV101 (gaboxadol) for the treatment of Angelman syndrome. OV101 is believed to be the only delta (δ)-selective GABA A receptor agonist in development and is currently be
-
Ovid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights Platform
6/8/2020
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced multiple presentations across its rare neurological disease platform are available on the 2020 American Academy of Neurology (AAN) Science Highlights platform. The presentations were originally slated for discussion at the AAN 72nd Annual Meeting scheduled for April 25
-
Ovid Therapeutics Launches Pipeline Teach-In Webinar Series
6/4/2020
Company to host first webinar on Wednesday, June 17, to review OV935 (soticlestat) development program for rare developmental and epileptic encephalopathies (DEE)